Abstract
In this issue of Blood, Goshua et al present a timely cost-effectiveness analysis of caplacizumab for immune thrombotic thrombocytopenic purpura (iTTP) and conclude that adding caplacizumab to standard-of-care (SOC) therapy with plasma exchange and immunosuppression is not cost-effective based on outcomes including duration of hospitalization and iTTP recurrence.
MeSH terms
-
ADAMTS13 Protein
-
Cost-Benefit Analysis
-
Humans
-
Purpura, Thrombotic Thrombocytopenic*
-
Single-Domain Antibodies*
Substances
-
Single-Domain Antibodies
-
caplacizumab
-
ADAMTS13 Protein